Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?
Future research holds great potential, especially in improving personalized treatment predictions. Therefore, it is not easy to define a 'definitive endpoint' for research, as discoveries and technological innovations continue to evolve.
Authors
- Dario Giuffrida (ORCID: https://orcid.org/0000-0001-6404-2304)
- Mariacarmela Santarpia
- Elena Sapuppo
- Dalila Tessitore (ORCID: https://orcid.org/0009-0000-1248-0038)
- Nicola Silvestris
- Antonella Argentiero (ORCID: https://orcid.org/0000-0001-9187-3891)
- Giuliana Ciappina (ORCID: https://orcid.org/0000-0003-0813-3126)
- Massimiliano Berretta (ORCID: https://orcid.org/0000-0002-9837-9148)
- Davide Quaresmini (ORCID: https://orcid.org/0000-0003-0384-3444)
- Paola Marino
Institutions
- University of Messina (IT)
- University of Ferrara (IT)
- Istituto Oncologico Veneto (IT)
- Istituto Tumori Bari (IT)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1080/13543784.2025.2552847
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00